Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
Clin Nucl Med. 2012 Feb;37(2):134-6. doi: 10.1097/RLU.0b013e31823ea59a.
There are various etiologies, which can result in nonosseous, nonurologic uptake in bone scintigraphy. This study aimed to evaluate the influence of the interval between gadolinium (Gd)-containing contrast of MRI and Tc-99m DPD (Tc-99m 3,3-diphosphono-1,2-propanedicarboxylic acid) on bone scintigraphy.
We retrospectively analyzed 1028 patients with bone scintigraphy performed between January 2010 and February 2011. All these 1028 patients had MRI contrast administration prior to bone scintigraphy. Fifty patients (8 women, 42 men) showed hepatic uptake on bone scintigraphy. The patients were subdivided into 2 groups (group A: MRI performed on the same day with bone scintigraphy, group B: MRI performed 1 or 2 days before bone scintigraphy).
Among 1028 subjects, hepatic uptake in patients with MRI and bone scintigraphy on the same day was shown in 39 of the 585 bone scintigraphies (6.67%), while hepatic uptake with interval of 1 and 2 days was visualized in 8 of the 186 (4.30%) and 3 of the 87 (3.45%) subjects. No patients with interval more than 2 days showed hepatic uptake of bone scintigraphy.
The interval between MRI with Gd-contrast and bone scintigraphy has an influence on hepatic uptake. Gd-containing contrast injection before bone scintigraphy within 2 days might affect the nonosseous uptake of Tc-99m DPD. At least 2 days of interval between MRI and bone scintigraphy might be needed to avoid hepatic uptake of bone scintigraphy.
有多种病因可导致骨闪烁显像出现非骨、非泌尿科摄取。本研究旨在评估 MRI 含钆对比剂与 Tc-99m DPD（Tc-99m 3,3-二膦酸-1,2-丙二羧酸）之间的时间间隔对骨闪烁显像的影响。
我们回顾性分析了 2010 年 1 月至 2011 年 2 月间进行骨闪烁显像的 1028 例患者。所有患者均在骨闪烁显像前行 MRI 对比剂注射。1028 例患者中有 50 例（8 例女性，42 例男性）显示肝脏摄取。患者分为 2 组（组 A：MRI 与骨闪烁显像同日进行，组 B：MRI 于骨闪烁显像前 1 或 2 天进行）。
在 1028 例患者中，585 例骨闪烁显像中，有 39 例（6.67%）在 MRI 和骨闪烁显像同日进行时显示肝脏摄取，而间隔 1 天和 2 天进行时分别有 8 例（4.30%）和 3 例（3.45%）显示肝脏摄取。间隔超过 2 天的患者无一例显示骨闪烁显像肝脏摄取。
MRI 含钆对比剂与骨闪烁显像之间的时间间隔对肝脏摄取有影响。在骨闪烁显像前 2 天内注射含钆对比剂可能会影响 Tc-99m DPD 的非骨摄取。MRI 与骨闪烁显像之间至少需要 2 天的间隔，以避免骨闪烁显像出现肝脏摄取。
